Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors
about
Insights into cardio-oncology: Polypharmacology of quinazoline-based α1-adrenoceptor antagonists.SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa i
P2860
Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors
@ast
Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors
@en
type
label
Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors
@ast
Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors
@en
prefLabel
Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors
@ast
Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors
@en
P2860
P356
P1476
Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors
@en
P2093
Serhan Kupeli
P2860
P304
P356
10.4330/WJC.V6.I7.555
P577
2014-07-01T00:00:00Z